A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

Status:	Active, not recruiting
Conditions:	Lung Cancer, Cancer
Therapuetic Areas:	Oncology
Healthy:	No
Age Range:	18 - Any
Updated:	3/9/2019
Start Date:	March 30, 2017
End Date:	July 3, 2019

A Phase 1/2 Study on the Safety of Rovalpituzumab Tesirine Administered in Combination With Nivolumab or Nivolumab and Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer

The purpose of this multicenter, Phase 1/2, open-label, study is to assess the safety and
efficacy of rovalpituzumab tesirine administered in combination with nivolumab or nivolumab
and ipilimumab in participants with extensive-stage small cell lung cancer (SCLC).

Inclusion Criteria:

- Participants with histologically or cytologically confirmed extensive-stage small cell
lung cancer (SCLC) with progressive disease after at least one platinum-based
chemotherapeutic regimen and with evaluable or measurable disease

- Eastern Cooperative Oncology Group (ECOG) 0-1

- Adequate hematologic, hepatic, and renal function

Exclusion Criteria:

- Has active, known, or suspected autoimmune disease

- Had prior exposure to an immuno-oncology or pyrrolobenzodiazepine (PBD)-based drug

We found this trial at

sites

Washington University School of Medicine /ID# 161011

660 South Euclid Avenue
Saint Louis, Missouri 63110

from

Saint Louis, MO